BioPharma Credit PLC (BOPCF)

BioPharma Credit Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Other Revenue	150.03	135.74	218.17	103.88	110.02
Revenue	150.03	135.74	218.17	103.88	110.02
Revenue Growth (YoY)	10.53%	-37.78%	110.02%	-5.58%	-27.09%
Gross Profit	150.03	135.74	218.17	103.88	110.02
Selling, General & Admin	27.72	27.28	35.79	18.95	20.87
Other Operating Expenses	0.13	0	0.04	-0.05	-
Operating Expenses	27.85	27.28	35.83	18.9	20.87
Operating Income	122.18	108.46	182.34	84.98	89.15
Currency Exchange Gain (Loss)	-0	-0.01	-0.03	-0.02	-0.01
Pretax Income	122.18	108.45	182.31	84.96	89.14
Net Income	122.18	108.45	182.31	84.96	89.14
Net Income to Common	122.18	108.45	182.31	84.96	89.14
Net Income Growth	12.66%	-40.51%	114.59%	-4.69%	-27.13%
Shares Outstanding (Basic)	1,222	1,309	1,364	1,374	1,374
Shares Outstanding (Diluted)	1,222	1,309	1,364	1,374	1,374
Shares Change (YoY)	-6.65%	-4.00%	-0.72%	-0.00%	-0.00%
EPS (Basic)	0.10	0.08	0.13	0.06	0.06
EPS (Diluted)	0.10	0.08	0.13	0.06	0.06
EPS Growth	20.68%	-38.03%	116.14%	-4.68%	-27.13%
Dividend Per Share	0.070	0.070	0.070	0.070	0.070
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	81.44%	79.90%	83.58%	81.80%	81.03%
Profit Margin	81.44%	79.90%	83.56%	81.79%	81.02%
EBIT	122.18	108.46	182.34	84.98	89.15
EBIT Margin	81.44%	79.90%	83.58%	81.80%	81.03%
Revenue as Reported	150.03	135.73	218.14	103.86	110.01

Updated Sep 23, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.